CTOs on the Move

Iomai Corporation

www.iomai.com

 
Iomai Corporation is a Gaithersburg, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.iomai.com
  • 20 Firstfield Rd Ste 250
    Gaithersburg, MD USA 20878
  • Phone: 301.556.4500

Executives

Name Title Contact Details

Similar Companies

IFM Therapeutics

At IFM Therapeutics, LLC, we work to improve the lives of patients with inflammatory disorders and cancer by developing transformative medicines that precisely target the innate immune system, the body`s first line of immunological response and an essential component of immune function.

EcoSynthetix

EcoSynthetix is a Lansing, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

High Point Clinical Trials Center

High Point Clinical Trials Center is committed to the safe and ethical conduct of clinical trials for investigational drugs in a pleasant, comfortable environment for research participants. We recognize the importance of your decision to participate in a clinical trial and strive to guide you through the process with a knowledgeable and exciting experience. Your decision of being a research participant today may benefit generations to come. Our research trials and clinical studies include research on Alzheimer`s, diabetes, overweight and healthy individuals, and encompass individuals from the Greensboro, Winston-Salem, High Point areas of North Carolina, as well as throughout the US. We offer spacious comfortable living quarters, entertainment areas (media and games rooms), catered meals and wireless internet service for our participants. High Point Clinical Trials Center offers clinical studies and trials for Greensboro, Winston Salem, High Point residents, as well as throughout the US.

ChemImage

ChemImage is a Pittsburgh, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kinnate

Kinnate Biopharma Inc. is a clinical-stage precision oncology company focused on expanding on the promise of targeted therapies for those battling cancer. The company is developing medicines for known oncogenic drivers where there are no approved targeted drugs and to overcome the limitations of marketed cancer therapies, such non-responsiveness or acquired and intrinsic resistance. Kinnate has two lead clinical programs being studied in solid tumors with RAF, NRAS and FGFR-driven alterations, and is rapidly progressing a pipeline of additional small molecule drug candidates as part of the Kinnate Discovery Engine.